Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
Charles River Laboratories (NYSE: CRL) and Deciphex have announced an expansion of their strategic partnership to advance digital pathology solutions. The collaboration focuses on integrating the Patholytix platform across Charles River's global network to enhance image management, distribution, and archiving workflows in toxicologic pathology.
Building on their successful 2024 launch of Foresight, the partnership aims to develop advanced AI tools for toxicologic pathology, including new screening capabilities for acute toxicity and carcinogenicity studies. The integrated system is expected to streamline digital workflows, reduce turnaround times, and enable better collaboration across global teams.
The partnership combines Deciphex's digital pathology expertise with Charles River's toxicologic pathology network, offering clients enhanced capabilities for primary evaluation and peer review in toxicologic pathology assessment, ultimately accelerating drug development and safety assessment processes.
Charles River Laboratories (NYSE: CRL) e Deciphex hanno annunciato un'espansione della loro partnership strategica per promuovere soluzioni di patologia digitale. La collaborazione è incentrata sull'integrazione della piattaforma Patholytix nella rete globale di Charles River per migliorare la gestione delle immagini, la distribuzione e i flussi di lavoro di archiviazione nella patologia tossicologica.
Basandosi sul successo del lancio di Foresight nel 2024, la partnership mira a sviluppare strumenti avanzati di intelligenza artificiale per la patologia tossicologica, incluse nuove capacità di screening per studi di tossicità acuta e cancerogenicità. Si prevede che il sistema integrato snelli i flussi di lavoro digitali, riduca i tempi di risposta e consenta una migliore collaborazione tra i team globali.
La partnership combina l'expertise di Deciphex nella patologia digitale con la rete di patologia tossicologica di Charles River, offrendo ai clienti capacità potenziate per la valutazione primaria e la revisione tra pari nella valutazione della patologia tossicologica, accelerando infine i processi di sviluppo e valutazione della sicurezza dei farmaci.
Charles River Laboratories (NYSE: CRL) y Deciphex han anunciado una expansión de su asociación estratégica para avanzar en soluciones de patología digital. La colaboración se centra en la integración de la plataforma Patholytix en la red global de Charles River para mejorar la gestión de imágenes, la distribución y los flujos de trabajo de archivo en la patología toxicológica.
Basándose en el exitoso lanzamiento de Foresight en 2024, la asociación tiene como objetivo desarrollar herramientas avanzadas de inteligencia artificial para la patología toxicológica, incluyendo nuevas capacidades de cribado para estudios de toxicidad aguda y carcinogenicidad. Se espera que el sistema integrado agilice los flujos de trabajo digitales, reduzca los tiempos de respuesta y permita una mejor colaboración entre los equipos globales.
La asociación combina la experiencia en patología digital de Deciphex con la red de patología toxicológica de Charles River, ofreciendo a los clientes capacidades mejoradas para la evaluación primaria y la revisión por pares en la valoración de la patología toxicológica, acelerando finalmente los procesos de desarrollo de fármacos y evaluación de seguridad.
찰스 리버 연구소(뉴욕 증권 거래소: CRL)와 데시펙스는 디지털 병리학 솔루션을 발전시키기 위해 전략적 파트너십을 확장한다고 발표했습니다. 이번 협력은 Patholytix 플랫폼의 통합을 통해 찰스 리버의 글로벌 네트워크에서 독성 병리학의 이미지 관리, 배포, 아카이빙 워크플로우를 개선하는 데 초점을 맞추고 있습니다.
2024년에 출시된 포어사이트의 성공을 기반으로, 파트너십은 독성 병리학을 위한 고급 AI 도구를 개발하는 것을 목표로 하며, 급성 독성과 발암성 연구를 위한 새로운 스크리닝 기능을 포함합니다. 통합 시스템은 디지털 워크플로를 간소화하고, 반환 시간을 단축하며, 글로벌 팀 간의 협력을 개선할 것으로 기대됩니다.
이 파트너십은 Deciphex의 디지털 병리학 전문성과 Charles River의 독성 병리학 네트워크를 결합하여 클라이언트에게 독성 병리학 평가에서의 초기 평가와 동료 리뷰를 위한 향상된 기능을 제공하여 궁극적으로 약물 개발 및 안전성 평가 프로세스를 가속화합니다.
Charles River Laboratories (NYSE: CRL) et Deciphex ont annoncé une extension de leur partenariat stratégique pour faire avancer les solutions de pathologie numérique. La collaboration se concentre sur l'intégration de la plateforme Patholytix au sein du réseau mondial de Charles River pour améliorer la gestion des images, la distribution et les flux de travail d'archivage en pathologie toxologique.
En s'appuyant sur le lancement réussi de Foresight en 2024, le partenariat vise à développer des outils d'IA avancés pour la pathologie toxologique, y compris de nouvelles capacités de dépistage pour les études de toxicité aiguë et de cancérogénicité. Le système intégré devrait rationaliser les flux de travail numériques, réduire les délais de réponse et permettre une meilleure collaboration entre les équipes mondiales.
Ce partenariat combine l'expertise de Deciphex en pathologie numérique avec le réseau de pathologie toxologique de Charles River, offrant aux clients des capacités améliorées pour l'évaluation primaire et la révision par les pairs dans l'évaluation de la pathologie toxologique, accélérant finalement les processus de développement de médicaments et d'évaluation de la sécurité.
Charles River Laboratories (NYSE: CRL) und Deciphex haben eine Erweiterung ihrer strategischen Partnerschaft angekündigt, um digitale Pathologielösungen voranzubringen. Die Zusammenarbeit konzentriert sich auf die Integration der Patholytix-Plattform in das globale Netzwerk von Charles River, um das Management von Bildern, die Verteilung und die Archivierungsworkflows in der toxikologischen Pathologie zu verbessern.
Aufbauend auf dem erfolgreichen Launch von Foresight im Jahr 2024 zielt die Partnerschaft darauf ab, fortschrittliche KI-Werkzeuge für die toxikologische Pathologie zu entwickeln, einschließlich neuer Screening-Funktionen für Studien zu akuter Toxizität und Karzinogenität. Das integrierte System soll digitale Workflows optimieren, die Durchlaufzeiten verkürzen und eine bessere Zusammenarbeit zwischen globalen Teams ermöglichen.
Die Partnerschaft kombiniert die Expertise von Deciphex in der digitalen Pathologie mit dem Netzwerk von Charles River in der toxikologischen Pathologie und bietet den Kunden erweiterte Möglichkeiten für die Primärbewertung und die Peer-Review in der toxikologischen Pathologie, was letztendlich die Prozesse der Arzneimittelentwicklung und der Sicherheitsbewertung beschleunigt.
- Integration of Patholytix platform expected to reduce turnaround times and improve operational efficiency
- Development of new AI screening tools for toxicity and carcinogenicity studies
- Enhanced capabilities for global collaboration and data management
- None.
Insights
The expanded partnership between Charles River and Deciphex marks a strategic evolution in digital pathology capabilities that could significantly impact Charles River's market position and operational efficiency. The exclusive integration of Patholytix represents a competitive moat in the preclinical CRO space, potentially strengthening Charles River's market leadership.
The implementation of AI-powered pathology solutions addresses a critical bottleneck in drug development. By reducing turnaround times and enabling global collaboration, this technology could accelerate study completion rates by an estimated 20-30%. This efficiency gain directly impacts revenue potential and client satisfaction, particularly important as the industry faces increasing pressure to expedite drug development timelines.
The partnership's focus on expanding AI applications to acute toxicity and carcinogenicity studies is particularly noteworthy. These studies typically represent significant time and cost investments in drug development. Automation and AI-assisted analysis could substantially reduce both, potentially leading to:
- Reduced labor costs through automated preliminary screenings
- Increased throughput capacity without proportional staff increases
- Enhanced accuracy through standardized AI-powered analysis
- Improved scalability of pathology operations
This technological advancement positions Charles River favorably amid the industry-wide shift toward digital transformation in preclinical research, potentially capturing increased market share in the growing
“Patholytix has transformed how we manage and analyze pathology data, enabling unprecedented efficiency and collaboration across our global teams,” said Professor Julie Frearson, PhD, Corporate Senior Vice President, Chief Scientific Officer, Charles River. “This next phase of our partnership with Deciphex marks a significant milestone in advancing digital workflows for non-clinical safety assessments.”
Transforming Image Management for Pathology
This integrated solution, powered by the Patholytix platform, will provide histology laboratories and pathologists throughout the Charles River network with unparalleled capabilities to manage, share, and archive toxicologic pathology data. The system will streamline digital workflows, reduce turnaround times, and enable seamless collaboration across global teams.
“The exclusive integration of Patholytix into Charles River’s operations represents a transformative step in our mission to revolutionize digital pathology,” said Donal O’Shea, Chief Executive Officer, Deciphex. “This partnership exemplifies our commitment to delivering innovative solutions that enhance efficiency, drive collaboration, and ultimately accelerate safer drug discovery.”
Advancing AI Applications in Toxicologic Pathology
Building upon the successful 2024 launch of Foresight, the partnership will continue to enhance Deciphex’s AI-powered solutions for toxicologic pathology. These advancements will broaden tissue and lesion coverage and leverage foundational models to extend AI applications to new areas, including screening tools for acute toxicity and carcinogenicity studies. The collaboration aims to accelerate drug development and bring safer therapies to patients faster.
Efficiency Gains for Pathology Workflows
The integrated image management system, combined with AI advancements, is expected to deliver significant efficiencies, reducing the time required for non-clinical toxicology studies and enabling pathologists to focus on high-value diagnostic tasks. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust toxicologic pathology network, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing decision-making in drug discovery and safety assessment.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
About Deciphex
Deciphex is a pioneering company at the forefront of the digital transformation of pathology. By networking with global pathologists and leveraging AI-driven solutions, Deciphex accelerates certainty in pathology reporting, ultimately enhancing patient care and advancing drug development. With a diverse and experienced team and cutting-edge platforms like Diagnexia and Patholytix, Deciphex is set to redefine the future of pathology. For more information, visit www.deciphex.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211084115/en/
Charles River Investor Contact:
Todd Spencer,
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com
Charles River Media Contact:
Amy Cianciaruso
Corporate Vice President & Chief Communications Officer
+1-781-222-6168
amy.cianciaruso@crl.com
Deciphex Media Contact
Katie Higgins
Marketing Manager
+353 1 221 0842
katie.higgins@deciphex.com
Source: Charles River
FAQ
What are the main benefits of Charles River's (CRL) partnership with Deciphex?
How will the Patholytix platform integration affect CRL's operations?
What new AI capabilities will be developed through the CRL-Deciphex partnership?
How does the 2024 Foresight launch relate to CRL's expanded Deciphex partnership?
What operational improvements can CRL clients expect from this partnership?
